Triosephosphate isomerase deficiency
| Triosephosphate isomerase deficiency | |
|---|---|
| Other names | Triose phosphate-isomerase deficiency [1] |
 | |
| Triosephosphate isomerase deficiency has an autosomal recessive pattern of inheritance. | |
| Specialty | Hematology  |
Triosephosphate isomerase deficiency is a rare autosomal recessive[2] metabolic disorder which was initially described in 1965.[3]
It is a unique glycolytic enzymopathy that is characterized by chronic haemolytic anaemia, cardiomyopathy, susceptibility to infections, severe neurological dysfunction, and, in most cases, death in early childhood.[4] The disease is exceptionally rare with fewer than 100 patients diagnosed worldwide.
Genetics
Thirteen different mutations in the respective gene, which is located at chromosome 12p13 and encodes the ubiquitous housekeeping enzyme triosephosphate isomerase (TPI), have been discovered so far.[4] TPI is a crucial enzyme of glycolysis and catalyzes the interconversion of dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. A marked decrease in TPI activity and an accumulation of dihydroxyacetone phosphate have been detected in erythrocyte extracts of homozygous (two identical mutant alleles) and compound heterozygous (two different mutant alleles) TPI deficiency patients. Heterozygous individuals are clinically unaffected, even if their residual TPI activity is reduced. Recent work suggests that not a direct inactivation, but an alteration in TPI dimerization might underlie the pathology.[2] This might explain why the disease is rare, but inactive TPI alleles have been detected at higher frequency implicating a heterozygote advantage of inactive TPI alleles.[citation needed]
The most common mutation causing TPI deficiency is TPI Glu104Asp. All carriers of the mutation are descendants of a common ancestor, a person that lived in what is today France or England more than 1000 years ago.[5]
Diagnosis
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section is empty. You can help by adding to it. (August 2017) |
Treatment
| This section is empty. You can help by adding to it. (August 2017) |
See also
References
- ^ "Triosephosphate isomerase deficiency | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 11 April 2019.
- ^ a b Ralser, Markus; Gino Heeren; Michael Breitenbach; Hans Lehrach; Sylvia Krobitsch (December 20, 2006). Janbon, Guilhem (ed.). "Triose Phosphate Isomerase Deficiency Is Caused by Altered Dimerization–Not Catalytic Inactivity–of the Mutant Enzymes". PLOS ONE. 1 (1): e30. Bibcode:2006PLoSO...1...30R. doi:10.1371/journal.pone.0000030. PMC 1762313. PMID 17183658.
- ^ Schneider, Arthur S.; William N. Valentine; Hattori M; H. L. Heins Jr (1965). "Hereditary Hemolytic Anemia with Triosephosphate Isomerase Deficiency". New England Journal of Medicine. 272 (5): 229–235. doi:10.1056/NEJM196502042720503. PMID 14242501.
- ^ a b Schneider, Arthur S. (Mar 2000). "Triosephosphate isomerase deficiency: historical perspectives and molecular aspects". Best Practice & Research Clinical Haematology. 13 (1): 119–140. doi:10.1053/beha.2000.0061. PMID 10916682.
- ^ Schneider A, Westwood B, Yim C, et al. (1996). "The 1591C mutation in triosephosphate isomerase (TPI) deficiency. Tightly linked polymorphisms and a common haplotype in all known families". Blood Cells Mol. Dis. 22 (2): 115–25. doi:10.1006/bcmd.1996.0019. PMID 8931952.